- Skyepharma, the French CDMO specialising in solid oral forms and complex molecules, has announced a leadership transition with Sébastien Mas appointed as the new CEO.
- The company, which achieved €29 million in turnover in 2024, enters a new phase of growth following the full acquisition by Oleron Pharma.
Skyepharma, a French CDMO (contract development and manufacturing organisation) based in Saint-Quentin-Fallavier near Lyon, has announced a change in leadership as Sébastien Mas takes over as Chief Executive Officer. The transition follows ten years of growth under outgoing president and shareholder David Lescuyer, who will continue to support the company during a transitional period.
The ownership of Skyepharma has been fully acquired by Oleron Pharma, with Bertrand Simon and Hervé Letoublon becoming new shareholders. Both bring expertise in strategic development and investment, aiming to sustain the company’s long-term vision and growth trajectory. Simon is the founder of BYCap, a consultancy specialising in business transmission, while Letoublon founded Jadel, an evergreen investment company known as Capital Patience.
Under Lescuyer’s leadership, Skyepharma expanded its capabilities beyond contract manufacturing into pharmaceutical development and bioproduction, with a focus on complex molecules such as oncology treatments. The company has grown from 80 to over 200 employees and tripled its revenue in nine years. Over the past three years, it has achieved 33% growth, reaching a turnover of €29 million in 2024.
The leadership change was carefully planned to ensure stability for employees and partners. Mas, who brings extensive industrial leadership experience, will guide Skyepharma’s next phase while maintaining its core values of transparency, caring, and excellence.
“Skyepharma represents a strong foundation to accelerate its future development, with significant potential already demonstrated by its growth trajectory,”
Bertrand Simon
